CD274 and head and neck squamous cell carcinoma: OncoPrism-HNSCC has a higher sensitivity than PD-L1 IHC (0.79 vs. 0.64, p = 0.005; Table 2), corresponding to a lower number of false negatives wherein the test incorrectly predicts progression.